Results 111 to 120 of about 80,006 (331)

Cambrian problematica and the diversification of deuterostomes [PDF]

BMC Biology, 2012
Vetulicolians are an enigmatic group of Cambrian organisms that have been affiliated at various times with arthropods, lobopodians, kinorhynchs and deuterostomes. New evidence on the structure of the lateral pores of vetulicolians published in BMC Biology strengthens the view that they may be total group deuterostomes, but unfortunately sheds no new ...
openaire   +4 more sources

Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial

European Journal of Heart Failure, EarlyView.
Baseline characteristics for the vericiguat global study in participants with chronic heart failure (VICTOR) trial. ARNI, angiotensin receptor/neprilysin inhibitor; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate; GDMT, guideline‐directed medical therapy; HF, heart failure; HFrEF, heart failure with reduced ejection ...
Clara I. Saldarriaga, Faiez Zannad, Ciaran J. McMullan, Aiwen Xing, Davis Gates, Kevin J. Anstrom, Marc P. Bonaca, Stefano Corda, Justin A. Ezekowitz, Carolyn S.P. Lam, Eldrin F. Lewis, JoAnn Lindenfeld, Robert J. Mentz, Christopher O'Connor, Mahesh Patel, Piotr Ponikowski, Yogesh N.V. Reddy, Giuseppe M.C. Rosano, Michele Senni, James Udelson, Adriaan A. Voors, Javed Butler   +21 more
wiley   +1 more source

Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial

European Journal of Heart Failure, EarlyView.
Finerenone and glycaemic status in patients with heart failure with mildly reduced/preserved ejection fraction. CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; RR, rate ratio. Abstract Aims The efficacy and safety of the non‐steroidal mineralocorticoid receptor antagonist, finerenone, have not been examined in patients
Jawad H. Butt, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Carolyn S.P. Lam, Meike Brinker, Patrick Schloemer, Prabhakar Viswanathan, Andrea Lage, Katja Rohwedder, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray   +18 more
wiley   +1 more source

Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial

European Journal of Heart Failure, EarlyView.
The beneficial effects of finerenone in patients with heart failure (HF) and mildly reduced or preserved ejection fraction were consistent, regardless of a history of chronic obstructive pulmonary disease (COPD) status. BMI, body mass index; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.
Jawad H. Butt, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Carolyn S.P. Lam, Katharina Mueller, Markus F. Scheerer, Prabhakar Viswanathan, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray   +16 more
wiley   +1 more source

The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS‐HF

European Journal of Heart Failure, EarlyView.
Effect of finerenone on a hierarchical endpoint. CI, confidence interval; CV, cardiovascular; EF, ejection fraction; HF, heart failure. ABSTRACT Aims FINEARTS‐HF demonstrated the efficacy of finerenone in reducing total worsening heart failure (HF) events (first and recurrent) and cardiovascular death, compared to placebo, in patients with HF and ...
Toru Kondo, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Meike Brinker, James Lay‐Flurrie, Patrick Schloemer, Prabhakar Viswanathan, Flaviana Amarante, Chern‐En Chiang, Gerasimos Filippatos, Carolyn S.P. Lam, Mark C. Petrie, Michele Senni, Morten Schou, Subodh Verma, Adriaan A. Voors, Dirk von Lewinski, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V McMurray   +23 more
wiley   +1 more source

The Cambrian Horizons of Comley (Shropshire), and their Brachiopoda, Pteropoda, Gasteropoda, etc. [PDF]

, 1920
Edgar Sterling Cobbold
openalex   +1 more source

Pegmatites of Southern California [PDF]

, 1954
For many years the southern California region has attracted the attention of geologists interested in pegmatites and pegmatite deposits, largely because of the well-known gem and lithium occurrences in San Diego and Riverside Counties. These world-famous
Jahns, Richard H.
core  

Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial

European Journal of Heart Failure, EarlyView.
ABSTRACT Aims Anaemia is common in heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and associated with poor clinical outcomes. While renin–angiotensin system blockers reduce haemoglobin, little is known about the effect of mineralocorticoid receptor antagonists on haemoglobin and in patients with anaemia.
Misato Chimura, Mingming Yang, Alasdair D. Henderson, Pardeep S. Jhund, Kieran F. Docherty, Brian L. Claggett, Akshay S. Desai, Gerasimos Filippatos, Grzegorz Gajos, Katharina Mueller, Andrea Glasauer, Katja Rohwedder, Prabhakar Viswanathan, Carolyn S.P. Lam, Naoki Sato, Michele Senni, Adriaan A. Voors, Faiez Zannad, Mehmet B. Yilmaz, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray, on behalf of the FINEARTS‐HF Committees and Investigators   +23 more
wiley   +1 more source

On the Pre-Cambrian (Dimetian, Arvonian, and Pebidian) Rocks in Caernarvonshire and Anglesey [PDF]

, 1879
Henry Hicks
openalex   +1 more source

Effects of finerenone on natriuretic peptide levels in heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial

European Journal of Heart Failure, EarlyView.
Abstract Aims N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) concentrations serve as markers of prognosis and therapeutic response in patients with heart failure (HF). The effect of the non‐steroidal mineralocorticoid receptor antagonist finerenone on NT‐proBNP in patients with HF with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF)
Jonathan W. Cunningham, Brian L. Claggett, Muthiah Vaduganathan, Akshay S. Desai, Pardeep S. Jhund, Carolyn S.P. Lam, Michele Senni, Sanjiv Shah, Adriaan Voors, Faiez Zannad, Bertram Pitt, Flaviana Amarante, James Lay‐Flurrie, Katja Rohwedder, Laura Goea, Mario Berger, John J.V. McMurray, Scott D. Solomon   +17 more
wiley   +1 more source